* Neurogene Inc is expected to report resultson August 8 (estimated) for the period ending June 30 2024
*
* LSEG's mean analyst estimate for Neurogene Inc is for a loss of $1.05 per share.
* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the last three months.
* Wall Street's median 12-month price target for Neurogene Inc is $51.00, above its last closing price of $37.87.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Mar. 31 2024 -1.12 -1.13 -1.00 Beat 11.9
Jan. 1 2024 -1.17 -1.17 -1.51 Missed -28.7
-1.64
-0.80
Mar. -2.51 -2.50 -5.12 Missed -104.8
31 2023
Sep. 30 2022 -3.80 -4.80 Missed -26.3
Sep. 30 2022 -5.94 -6.09 -4.80 Beat 21.1
Jan. 1 0001 -5.95 -6.00 -5.60 Beat 6.7
This summary was machine generated August 7 at 02:55 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
Comments